Oncolytics Biotech Inc.
ONCY
Rank in Stocks
#23570
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in... Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Share Price
$0.4077
Last synced: 2026-11-09
Market Cap
$40.92M
Change (1 day)
-7.21%
Change (1 year)
-64.24%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncolytics Biotech Inc. (ONCY)
Category
Healthcare
EPS for Oncolytics Biotech Inc. (ONCY)
EPS as of June 2026 TTM: $-0.34
According to Oncolytics Biotech Inc.'s latest financial reports, its current EPS (TTM) is $-0.34. At the end of 2025 the company had an EPS of $-0.30, a decrease compared to its 2024 EPS of $-0.21.
EPS history for Oncolytics Biotech Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.34 | 13.33% |
| 2025 | $-0.30 | 42.92% |
| 2024 | $-0.21 | -32.45% |
| 2023 | $-0.31 | -4.59% |
| 2022 | $-0.32 | -16.35% |
| 2021 | $-0.39 | 2.81% |
| 2020 | $-0.38 | -67.31% |
| 2019 | $-1.15 | 47.61% |
| 2018 | $-0.78 | -12.25% |
| 2017 | $-0.89 | -0.36% |
| 2016 | $-0.89 | 6.88% |
| 2015 | $-0.84 | -51.65% |
| 2014 | $-1.73 | -31.35% |
| 2013 | $-2.52 | -44.82% |
| 2012 | $-4.57 | 19.90% |
| 2011 | $-3.81 | 24.84% |
| 2010 | $-3.05 | -2.22% |
| 2009 | $-3.12 | -5.56% |
| 2008 | $-3.30 | -11.41% |
| 2007 | $-3.73 | 15.50% |
| 2006 | $-3.23 | 1.20% |
| 2005 | $-3.19 | -10.96% |
| 2004 | $-3.58 | 32.77% |
| 2003 | $-2.70 | 55.36% |
| 2002 | $-1.74 | -12.72% |
| 2001 | $-1.99 | 42.82% |
| 2000 | $-1.39 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -4,705.88% |
US
|
|
| $-7.07 | 1,979.41% |
US
|
|
| $-5.29 | 1,455.88% |
AU
|
|
| $12.88 | -3,888.26% |
BE
|
|
| $21.56 | -6,441.18% |
NL
|
Questions about Oncolytics Biotech Inc.'s earnings per share (EPS)
What is Oncolytics Biotech Inc.'s earnings per share (EPS)?
Oncolytics Biotech Inc.'s earnings per share (EPS) over the last twelve months is $-0.34, as of Jun 2026.
What was Oncolytics Biotech Inc.'s earnings per share (EPS) in 2025?
In 2025, Oncolytics Biotech Inc.'s earnings per share (EPS) was $-0.30, compared with $-0.21 in 2024.
How has Oncolytics Biotech Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Oncolytics Biotech Inc.'s earnings per share (EPS) was highest in 2024 ($-0.21) and lowest in 2021 ($-0.39).
How does Oncolytics Biotech Inc.'s earnings per share (EPS) compare with similar companies?
Oncolytics Biotech Inc.'s earnings per share (EPS) ($-0.34) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.